MINIMASTER – IMMUNOTHERAPY, INNOVATION AND BREAST CANCER – III EDITION

1. 1.Schmid P, Cortes J, Dent R, et al.. Event-free Survival with Pembrolizumab in Early Triple-Negative Breast Cancer. N Engl J Med. 2022;386:556-567. (Aggiornamento dello studio KEYNOTE-522).. 2022
   Articolo scientificoN Engl J Med. 2022;386:556-567. (Aggiornamento dello studio KEYNOTE-522).Leggi il PDF gratuito
2. 2.Schmid P, Cortes J, Pusztai L, et al.. Pembrolizumab for Early Triple-Negative Breast Cancer.. N Engl J Med. 2020;382:810-821. Studio registrativo KEYNOTE-522.. 2020
   Articolo scientificoN Engl J Med. 2020;382:810-821. Studio registrativo KEYNOTE-522.Leggi il PDF gratuito
3. 3.Loibl S, Poortmans P, Morrow M, Denkert C, Curigliano G.. Breast cancer. Lancet. 2021;397(10286):1750-1769.. 2021
   Articolo scientificoLancet. 2021;397(10286):1750-1769.Leggi il paperCerca versione gratuita
4. 4.Curigliano G, Burstein HJ, Winer EP, et al.. Early breast cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up.. Ann Oncol. Aggiornamento 2023-2025.NCCN Clinical Practice Guidelines in Oncology – Breast Cancer. 2025
   Articolo scientificoAnn Oncol. Aggiornamento 2023-2025.NCCN Clinical Practice Guidelines in Oncology – Breast CancerLeggi il paperCerca versione gratuita
5. 5.ANJ, Garber JE, Kaufman B, et al.. Adjuvant Olaparib for Patients with BRCA1- or BRCA2-Mutated Breast Cancer (OlympiA Trial).. N Engl J Med. 2021;384:2394-2405. 2021
   Articolo scientificoN Engl J Med. 2021;384:2394-2405Cerca su Google Scholar
6. 6.Masuda N, Lee SJ, Ohtani S, et al.. Adjuvant Capecitabine for Breast Cancer after Preoperative Chemotherapy (CREATE-X Trial).. N Engl J Med. 2017;376:2147-2159. 2017
   Adjuvant Capecitabine for Breast Cancer after Preoperative Chemotherapy (CREATE-X Trial).
   LibroAcquista su Amazon
7. 7.Salgado R, Denkert C, Campbell C, et al.. Tumor-Infiltrating Lymphocytes and the International Immuno-Oncology Biomarker Working Group Recommendations.. Ann Oncol. ESMO Guidelines – Management of Toxicities from Immunotherapy. 2020
   Articolo scientificoAnn Oncol. ESMO Guidelines – Management of Toxicities from ImmunotherapyCerca su Google Scholar

I link ai libri possono contenere un codice affiliato Amazon: in qualità di affiliato, ECM Finder potrebbe ricevere una commissione sugli acquisti idonei, senza alcun costo aggiuntivo per te. I link ai paper rimandano alla fonte scientifica (DOI, versione open-access o ricerca accademica).